A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors - Trial NCT06307925
Access comprehensive clinical trial information for NCT06307925 through Pure Global AI's free database. This Phase 1 trial is sponsored by HC Biopharma Inc. and is currently Recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 122 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
HC Biopharma Inc.
Timeline & Enrollment
Phase 1
Mar 27, 2024
Dec 31, 2025
Primary Outcome
Incidence of dose-limiting toxicity,Adverse events,serious adverse events,Maximum Tolerated Dose,Recommended Dose for Phase II Clinical Studies
Summary
This clinical trial is a multicenter, open, single-arm, non-randomized, dose-escalation and
 dose-expansion, phase I clinical study in patients with advanced recurrent or metastatic
 solid tumors.The goal of this study is to evaluate the safety and tolerability of HC010
 monotherapy in patients with advanced solid tumors.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06307925
Non-Device Trial